Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

This recommendation is based on data from the phase III MANDARA study, which compared a single monthly injection of Fasenra to three injections per month of GSK’s GSK blockbuster drug ...

AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation ... and AZ's IL-5 inhibitor Fasenra (benralizumab) - which competes ...

5,7 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks.4,5 In the trial, ...

Two of AstraZeneca’s most important drugs have received a boost, after European regulators backed a pen allowing people ... option for asthma injection Fasenra (benralizumab), based on a new ...

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...

The global injection pen market is expanding at a fast rate with the growing prevalence of chronic diseases, and increasing demand for convenient self-administration options. This trend is a move ...

Fasenrarecommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis New indication supported by the MANDARA trial which showed nearly 60% of ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca's Fasenra ...

AstraZeneca bioPharmaceuticals business unit executive vice-president Ruud Dobber stated: “Today’s approval of Fasenra, with its convenient, single-monthly injection, is a positive step ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...